CG
Publications
184
Views
83 563
Downloads
20 394
Supervised works
11
Items per page
1 - 184 of 184
Title Published in Access level OA Policy Year Views Downloads
Alerte au feu : des nanopompiers pour combattre les flammes de la polyarthrite rhumatoïdeRevue médicale suisse
accessLevelRestricted
2024 76 4
Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritisFrontiers in cardiovascular medicine
accessLevelPublic
2024 48 16
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesJoint bone spine
accessLevelPublic
2024 23 8
IL-18 Binding Protein–Producing Cells Attenuate Anemia in Murine Macrophage Activation SyndromeThe Journal of immunology
accessLevelPublic
2023 83 50
Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseasesFrontiers in immunology
accessLevelPublic
2023 66 25
Reporting and Representativeness of Race, Ethnicity, and Socioeconomic Status in Systemic Sclerosis Randomized Trials: An Observational StudyArthritis care & research
accessLevelPublic
2023 18 6
Special Issue “IL-1 family cytokines in host defense, inflammation and cancer”Cytokine
accessLevelPublic
2022 144 75
Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controlsVaccine
accessLevelRestricted
2022 25 0
Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction ModelingArthritis & rheumatology
accessLevelPublic
2022 57 23
Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the jointsCytokine
accessLevelPublic
2022 124 88
Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritisRheumatology
accessLevelPublic
2021 309 288
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesRheumatology
accessLevelRestricted
2021 186 0
Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes using disease-related blood biomarkersArthritis and Rheumatology
accessLevelPublic
2021 123 212
Intracellular IL-1 receptor antagonist isoform 1 released from keratinocytes upon cell death acts as an inhibitor for the alarmin IL-1αJournal of Immunology
accessLevelRestricted
2020 293 2
Response to: 'When binary and continuous responses disagree' by Dr OuyangAnnals of the Rheumatic Diseases
accessLevelRestricted
2020 276 2
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational toolsClinical and Experimental Rheumatology
accessLevelPublic
2020 204 61
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritisArthritis Research and Therapy
accessLevelPublic
2020 355 87
IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitisLife Science Alliance
accessLevelPublic
2020 137 355
Individual therapeutic DAS28-d crit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studiesRheumatology International
accessLevelPublic
2020 165 40
Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva CocktailClinical Pharmacology and Therapeutics
accessLevelPublic
2020 263 295
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbiditiesRMD Open
accessLevelPublic
2020 94 36
IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndromeRheumatology
accessLevelRestricted
2020 226 0
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trialThe Lancet
accessLevelRestricted
2020 198 0
The role of the IL-1 system in pregnancy and the use of IL-1 system markers to identify women at risk for pregnancy complications†Biology of Reproduction
accessLevelRestricted
2020 95 0
IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndromeRheumatology
accessLevelRestricted
2020 269 1
Production of IL-18 Binding Protein by Radiosensitive and Radioresistant Cells in CpG-Induced Macrophage Activation SyndromeJournal of Immunology
accessLevelRestricted
2020 224 1
Randomized clinical trials in ANCA-associated vasculitis: a systematic analysis of the WHO - International Clinical Trials Registry PlatformOrphanet Journal of Rare Diseases
accessLevelPublic
2020 110 82
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomesArthritis Research and Therapy
accessLevelPublic
2020 109 52
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in SwitzerlandRMD Open
accessLevelPublic
2020 132 55
Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the diseaseRheumatology
accessLevelRestricted
2020 255 8
Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational studyTravel Medicine and Infectious Disease
accessLevelRestricted
2020 113 0
Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumabAdvances in Rheumatology
accessLevelPublic
2019 231 108
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolutionRheumatology
accessLevelRestricted
2019 303 0
Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort studyRheumatology
accessLevelRestricted
2019 255 0
The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritisBritish Journal of Haematology
accessLevelRestricted
2019 199 0
Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohortRheumatology
accessLevelRestricted
2019 229 0
Long-term therapy with anakinra in hidradenitis suppurativa in three patientsInternational Journal of Dermatology
accessLevelRestricted
2019 253 1
Inadequate reporting of concomitant medications in rheumatology randomized controlled trials of pharmacologic interventionsSeminars in Arthritis and Rheumatism
accessLevelRestricted
2019 232 0
Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritisRMD Open
accessLevelPublic
2019 272 70
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritisSeminars in Arthritis and Rheumatism
accessLevelPublic
2019 263 135
Prevotella copri in individuals at risk for rheumatoid arthritisAnnals of the Rheumatic Diseases
2019 357 0
Variable domain N-linked glycosylation and negative surface charge are key features of monoclonal ACPA: Implications for B-cell selectionEuropean Journal of Immunology
accessLevelRestricted
2018 346 0
Biological agents in the management of adult-onset Still's diseaseJoint, Bone, Spine
accessLevelPublic
2018 374 228
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaborationAnnals of the Rheumatic Diseases
accessLevelRestricted
2018 416 1
Inflammasome Adaptor ASC Suppresses Apoptosis of Gastric Cancer Cells by an IL18-Mediated Inflammation-Independent MechanismCancer Research
accessLevelRestricted
2018 351 0
Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registriesRMD Open
accessLevelPublic
2018 276 114
Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in miceBlood
accessLevelRestricted
2018 415 2
Regulation and function of interleukin-36 cytokinesImmunological Reviews
accessLevelRestricted
2018 400 0
Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET studyRMD Open
accessLevelPublic
2018 359 139
β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin SecretionCell Reports
accessLevelPublic
2018 552 234
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndromeBlood
accessLevelRestricted
2018 292 1
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's diseaseAnnals of the Rheumatic Diseases
accessLevelPublic
2018 388 168
Comparison of Serological Biomarkers in Rheumatoid Arthritis and Their Combination to Improve Diagnostic PerformanceFrontiers in Immunology
accessLevelPublic
2018 337 184
Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritisArthritis Care and Research
accessLevelPublic
2018 378 366
Nanocrystal-Polymer Particles: Extended Delivery Carriers for Osteoarthritis TreatmentSmall
accessLevelPublic
2018 578 358
The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritisSwiss Medical Weekly
accessLevelPublic
2017 526 255
Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritisRheumatology
accessLevelRestricted
2017 451 5
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritisClinical Rheumatology
accessLevelRestricted
2017 522 3
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibitionJournal of Allergy and Clinical Immunology
accessLevelRestricted
2017 384 2
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnnals of the Rheumatic Diseases
accessLevelRestricted
2017 391 2
International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosusAutoimmunity Reviews
accessLevelRestricted
2017 341 1
Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trialsRMD Open
accessLevelPublic
2017 347 213
Cardiovascular risk in patients with rheumatoid arthritisSeminars in Immunopathology
accessLevelRestricted
2017 387 0
Rheumatoid arthritis: from basic findings and clinical manifestations to future therapiesSeminars in Immunopathology
accessLevelRestricted
2017 287 0
Granzyme A Contributes to Inflammatory Arthritis in Mice Through Stimulation of OsteoclastogenesisArthritis and Rheumatology
accessLevelRestricted
2017 468 0
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA CollaborationJournal of Rheumatology
accessLevelRestricted
2017 381 1
Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesisPLOS ONE
accessLevelPublic
2017 414 141
Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotypePloS one
accessLevelPublic
2017 499 205
IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitroAnnals of the Rheumatic Diseases
accessLevelRestricted
2017 380 0
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumabRMD Open
accessLevelPublic
2017 331 168
The role of female hormonal factors in the development of rheumatoid arthritisRheumatology
accessLevelRestricted
2017 401 0
Deficiency in IL-1 Receptor Type 2 Aggravates K/BxN Serum Transfer-Induced Arthritis in Mice but Has No Impact on Systemic Inflammatory ResponsesJournal of Immunology
accessLevelRestricted
2017 705 2
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial SpondyloarthritisArthritis & rheumatology
accessLevelRestricted
2016 446 0
A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated diseaseArthritis Research and Therapy
accessLevelPublic
2016 1 005 271
Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's diseaseClinical and experimental immunology
accessLevelRestricted
2016 467 2
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritisAnnals of the rheumatic diseases
accessLevelPublic
2016 464 197
Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokinesCytokine
accessLevelRestricted
2016 461 1
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative studyAnnals of the rheumatic diseases
accessLevelRestricted
2016 461 0
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritisRheumatology
accessLevelRestricted
2016 484 0
IL-1R1-MyD88 axis elicits papain-induced lung inflammationEuropean Journal of Immunology
accessLevelRestricted
2016 437 0
IL-36-Induced Toxicity in Neonatal Mice Involves TNF-α Production by Liver Myeloid CellsJournal of Immunology
accessLevelRestricted
2016 478 2
Elevated serum levels of free interleukin-18 in adult-onset Still's diseaseRheumatology
accessLevelRestricted
2016 485 0
SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotypeJournal of leukocyte biology
accessLevelRestricted
2016 452 1
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaborationArthritis Research and Therapy
accessLevelPublic
2016 422 172
Effect of particle size on the biodistribution of nano- and microparticles following intra-articular injection in miceInternational journal of pharmaceutics
accessLevelRestricted
2016 820 4
The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseasesCytokine
accessLevelRestricted
2015 176 0
Limited Contribution of IL-36 versus IL-1 and TNF Pathways in Host Response to Mycobacterial InfectionPloS one
accessLevelPublic
2015 495 197
Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management RegistryRheumatology
accessLevelRestricted
2015 450 0
Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signalingImmunity, inflammation and disease
accessLevelPublic
2015 1 127 168
The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologistsDermatology
2015 404 0
Severe Neutrophil-Dominated Inflammation and Enhanced Myelopoiesis in IL-33-Overexpressing CMV/IL33 MiceThe Journal of immunology
accessLevelRestricted
2015 624 2
Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal studyArthritis research & therapy
accessLevelPublic
2015 488 435
Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort StudyInflammatory bowel diseases
accessLevelRestricted
2015 439 0
Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release systemEuropean journal of pharmaceutics and biopharmaceutics
accessLevelRestricted
2015 621 4
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeuticsArthritis research & therapy
accessLevelPublic
2014 504 309
Immune-mediated experimental arthritis in IL-33 deficient miceCytokine
accessLevelRestricted
2014 606 0
Inflammation: IL-36 has proinflammatory effects in skin but not in jointsNature reviews. Rheumatology
accessLevelRestricted
2014 532 0
Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and kneeInternational orthopaedics
accessLevelRestricted
2014 534 0
Joint damage progression in patients with rheumatoid arthritis in clinical remission. Do biologics perform better than synthetic antirheumatic drugs?Journal of rheumatology
accessLevelRestricted
2014 464 0
Traitement de fond de la polyarthrite rhumatoïdeRevue médicale suisse
accessLevelRestricted
2014 234 2
Biological agents in monotherapy for the treatment of rheumatoid arthritisSchweizerische medizinische Wochenschrift
accessLevelRestricted
2014 501 2
In Black Africans with rheumatoid arthritis, ACPA recognize citrullinated fibrinogen and the derived peptides α36-50Cit38,42 and β60-74Cit60,72,74, like in CaucasiansClinical immunology
accessLevelRestricted
2014 569 1
Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumourAnnals of the rheumatic diseases
accessLevelRestricted
2014 584 2
Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in goutArthritis & rheumatology
accessLevelRestricted
2014 643 0
The severity of experimental arthritis is independent of IL-36 receptor signalingArthritis research & therapy
accessLevelPublic
2013 583 218
Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditionsJournal of leukocyte biology
accessLevelPublic
2013 490 465
Reply to Xie et al. about the article "Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis"Joint bone spine
accessLevelRestricted
2013 513 0
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementAnnals of the rheumatic diseases
accessLevelPublic
2013 639 431
Hand osteoarthritis: new insightsJoint bone spine
accessLevelRestricted
2013 545 0
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditionsAnnals of the rheumatic diseases
accessLevelPublic
2013 568 345
Tocilizumab versus adalimumab for rheumatoid arthritis - Authors' replyLancet
accessLevelRestricted
2013 497 0
Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiencyArthritis research & therapy
accessLevelPublic
2013 589 237
Recommendations for the use of ultrasound in rheumatoid arthritis: literature review and SONAR score experienceSchweizerische medizinische Wochenschrift
accessLevelPublic
2013 781 381
Do synovial leptin levels correlate with pain in end stage arthritis?International orthopaedics
accessLevelPublic
2013 618 146
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trialLancet
accessLevelRestricted
2013 573 0
The Activity of CCL18 is Principally Mediated through Interaction with GlycosaminoglycansFrontiers in immunology
accessLevelPublic
2013 538 272
Endogenous IL-1α is a chromatin-associated protein in mouse macrophagesCytokine
accessLevelRestricted
2013 562 1
Coexistence of seropositive rheumatoid arthritis and SAPHO syndromeJoint bone spine
accessLevelRestricted
2013 567 0
Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trialAnnals of the rheumatic diseases
accessLevelRestricted
2012 617 0
Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatmentsArthritis and rheumatism
accessLevelRestricted
2012 519 1
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonistsAnnals of the rheumatic diseases
accessLevelPublic
2012 502 375
Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritisJoint bone spine
accessLevelPublic
2012 672 625
Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?Arthritis care & research
accessLevelRestricted
2012 646 0
Mice deficient in hepatocyte-specific IL-1Ra show delayed resolution of concanavalin A-induced hepatitisEuropean Journal of Immunology
accessLevelRestricted
2012 550 3
The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promotersJournal of leukocyte biology
accessLevelPrivate
2012 617 0
Investigation of Caucasian rheumatoid arthritis susceptibility loci in African patients with the same diseaseArthritis research & therapy
accessLevelPublic
2012 635 321
IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cellsBlood
accessLevelPublic
2012 745 828
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaborationAnnals of the rheumatic diseases
accessLevelRestricted
2012 552 1
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid ArthritisAnnals of the rheumatic diseases
accessLevelPublic
2012 644 544
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patientsAnnals of the rheumatic diseases
accessLevelRestricted
2012 600 0
Articular inflammation is controlled by myeloid cell-derived interleukin 1 receptor antagonist during the acute phase of arthritis in miceAnnals of the rheumatic diseases
accessLevelRestricted
2012 605 0
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipientsHaematologica
accessLevelPublic
2011 961 558
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registriesAnnals of the rheumatic diseases
accessLevelRestricted
2011 492 0
IL-36R ligands are potent regulators of dendritic and T cellsBlood
accessLevelRestricted
2011 597 0
Spontaneous secretion of interleukin-17 and -22 by human cervical cells in Chlamydia trachomatis infectionMicrobes and infection
accessLevelRestricted
2011 568 0
Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single centerArthritis and rheumatism
accessLevelRestricted
2011 554 0
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center studyArthritis and rheumatism
accessLevelRestricted
2011 797 8
IL-33 biology with potential insights into human diseasesNature reviews. Rheumatology
accessLevelRestricted
2011 566 0
Absence of up-regulation for a proliferation-inducing ligand in Sjögren's sialadenitis lesionsRheumatology
accessLevelRestricted
2011 622 1
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort studyRheumatology
accessLevelRestricted
2011 559 0
Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritisArthritis and rheumatism
accessLevelRestricted
2011 605 0
Polyarthrite rhumatoïde,méthotrexate et fibrose pulmonaire : quelles évidences ?Revue médicale suisse
accessLevelRestricted
2010 714 1
Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteinsBMC immunology
accessLevelPublic
2010 543 490
Distinct roles of hepatocyte- and myeloid cell-derived IL-1 receptor antagonist during endotoxemia and sterile inflammation in miceThe Journal of immunology
accessLevelRestricted
2010 508 0
Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonistsJoint bone spine
accessLevelRestricted
2010 679 0
Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonistArthritis and rheumatism
accessLevelRestricted
2010 561 0
Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patientsJoint bone spine
accessLevelRestricted
2010 564 0
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the rheumatic diseases
accessLevelRestricted
2010 578 0
Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patientsArthritis research & therapy
accessLevelPublic
2010 628 501
Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritisArthritis and rheumatism
accessLevelRestricted
2010 761 3
IL-1 pathways in inflammation and human diseasesNature reviews. Rheumatology
accessLevelRestricted
2010 668 1
The effect of alcohol on radiographic progression in rheumatoid arthritisArthritis and rheumatism
accessLevelRestricted
2010 541 0
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?Annals of the rheumatic diseases
accessLevelRestricted
2010 534 0
Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trialArthritis and rheumatism
accessLevelRestricted
2010 614 0
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritisArthritis and rheumatism
accessLevelRestricted
2009 610 0
Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapiesSchweizerische medizinische Wochenschrift
accessLevelPublic
2009 558 247
Non-infectious lupus pericarditis: a retrospective hospital-based observation in Yaounde-CameroonClinical rheumatology
accessLevelRestricted
2009 538 0
Magnetically retainable microparticles for drug delivery to the joint: efficacy studies in an antigen-induced arthritis model in miceArthritis research & therapy
accessLevelPublic
2009 737 763
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritisArthritis and rheumatism
accessLevelRestricted
2009 544 0
Mutations in the IL1RN locus lead to autoinflammationNature reviews. Rheumatology
accessLevelRestricted
2009 532 0
Relationship between gamma-interferon and interleukin-17 in Chlamydia trachomatis reactive arthritisClinical and Experimental Rheumatology
2009 501 0
Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failureJoint bone spine
accessLevelRestricted
2009 510 0
The biological and clinical importance of the 'new generation' cytokines in rheumatic diseasesArthritis research & therapy
accessLevelPublic
2009 549 133
Adaptive immune response in JAM-C-deficient mice: normal initiation but reduced IgG memoryThe Journal of immunology
accessLevelRestricted
2009 528 0
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based studyAnnals of the rheumatic diseases
accessLevelRestricted
2009 517 0
Interleukin-33 is biologically active independently of caspase-1 cleavageThe Journal of biological chemistry
accessLevelPublic
2009 587 462
Synovial tissues concentrate secreted APRILArthritis research & therapy
accessLevelPublic
2009 591 341
The proinflammatory cytokine response to Chlamydia trachomatis elementary bodies in human macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator, through TLR2/TLR1/TLR6 and CD14The Journal of immunology
accessLevelRestricted
2008 572 0
Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis?Nature reviews. Rheumatology
accessLevelRestricted
2008 546 0
IL-1, IL-18, and IL-33 families of cytokinesImmunological reviews
accessLevelPublic
2008 793 3 195
Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated discSpine
accessLevelRestricted
2008 616 0
Impaired counter-regulation of interleukin-1 by the soluble IL-1 receptor type II in patients with chronic liver diseaseScandinavian journal of gastroenterology
accessLevelRestricted
2008 572 0
The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33Cytokine
accessLevelRestricted
2008 627 0
At the horizon of innovative therapy in rheumatology: new biologic agentsCurrent opinion in rheumatology
accessLevelRestricted
2008 570 0
Molecular Characterization and Subcellular Localization of Macrophage Infectivity Potentiator, a Chlamydia trachomatis LipoproteinJournal of Bacteriology
accessLevelPublic
2007 662 663
Expression and function of junctional adhesion molecule-C in human and experimental arthritisArthritis research & therapy
accessLevelPublic
2007 588 316
Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cellsCytokine
accessLevelRestricted
2007 468 0
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agentsArthritis and rheumatism
accessLevelRestricted
2007 111 1
Leukocyte migration to rheumatoid joints: Enzymes take overArthritis and rheumatism
accessLevelRestricted
2006 528 1
Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritisClinical and Experimental Rheumatology
accessLevelRestricted
2006 476 0
The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytesArthritis research & therapy
accessLevelPublic
2006 514 234
Intracellular interleukin-1 receptor antagonist type 1 antagonizes the stimulatory effect of interleukin-1 alpha precursor on cell motilityCytokine
accessLevelPublic
2005 474 381
Delayed resolution of acute inflammation during zymosan-induced arthritis in leptin-deficient miceArthritis research & therapy
accessLevelPublic
2004 430 149
Total hip prosthetic joint infection due to Veillonella speciesJoint bone spine
accessLevelRestricted
2004 585 0
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack